A drug that blocks multiple mutant forms of the RAS oncoprotein at once — relevant to neoantigen work because the same KRAS mutations are also shared-neoantigen vaccine targets.
RAS genes (KRAS, NRAS, HRAS) are among the most commonly mutated in cancer and were long considered undruggable. The first approved drugs hit only one specific mutation (KRAS G12C). A pan-RAS inhibitor aims wider — blocking many mutant RAS forms, including the G12D and G12V mutations that dominate pancreatic and colorectal cancer — often by trapping RAS in its active, signalling state.
This sits in neoag's landscape rather than its core, but the overlap is real and worth understanding: the exact KRAS mutations a pan-RAS drug targets — G12D, G12V — are the same shared neoantigens that KRAS-directed vaccines and TCR-T therapies aim at. A small molecule that validates hitting mutant RAS both confirms the target is worth chasing and raises the bar an immunotherapy must clear. ASCO 2026's daraxonrasib (a pan-RAS inhibitor) roughly doubled median survival versus chemotherapy in metastatic pancreatic cancer, a setting where vaccines such as the KRAS-amphiphile ELI-002 are also in development.
A pan-RAS inhibitor is a drug that blocks multiple mutant forms of the RAS oncoprotein simultaneously — not just the single KRAS G12C mutation that earlier drugs targeted, but also G12D, G12V and others — frequently by locking RAS in its active state so it cannot signal.
Because they target the same mutations. The KRAS hotspots a pan-RAS drug blocks (G12D, G12V) are also shared-neoantigen targets for KRAS-directed cancer vaccines and TCR-T therapies. A small molecule succeeding against mutant RAS validates the target and sets the comparator bar that immunotherapies are measured against.